Enveric Biosciences, Inc. (ENVB) Bundle
A Brief History of Enveric Biosciences, Inc. (ENVB)
Company Overview
Enveric Biosciences, Inc. is a biotechnology company focused on developing psychedelic-based therapeutics for mental health conditions.
Financial Performance
| Ticker Symbol | ENVB |
| Stock Price (as of January 2024) | $0.16 |
| Market Capitalization | $4.5 million |
| Annual Revenue (2022) | $0.3 million |
| Net Loss (2022) | $14.8 million |
Research and Development Pipeline
- Focusing on psilocybin-based therapeutics for mental health disorders
- Developing compounds for cancer-related psychological distress
- Exploring treatments for depression and anxiety
Key Milestones
2021: Merger between MYND Life Sciences and Brain Therapeutics
Corporate Structure
| Headquarters | Vancouver, British Columbia, Canada |
| CEO | Joseph Hsu |
| Number of Employees | Approximately 12 |
Regulatory Status
Conducting clinical trials under FDA investigational protocols
A Who Owns Enveric Biosciences, Inc. (ENVB)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| Sabby Management, LLC | 1,150,000 | 9.43% |
| Vanguard Group Inc. | 222,101 | 1.82% |
| Renaissance Technologies LLC | 164,200 | 1.35% |
Insider Ownership
As of the latest SEC filing, key insider ownership includes:
- Joseph Tucker (CEO) - 250,000 shares
- David Snyder (CFO) - 75,000 shares
- Board of Directors collectively - 350,000 shares
Public Float
Total public float: 12,190,000 shares
Ownership Structure
Public Ownership Percentage: 85.6%
Insider Ownership Percentage: 3.2%
Institutional Ownership Percentage: 11.2%
Enveric Biosciences, Inc. (ENVB) Mission Statement
Company Overview
Enveric Biosciences, Inc. is a biotechnology company focused on developing psychedelic-based therapeutics for neurological and psychiatric conditions.
Key Strategic Focus Areas
- Developing novel psychedelic-derived therapeutic compounds
- Targeting mental health and neurological disorders
- Advancing precision medicine approaches
Financial Profile
| Metric | 2023 Data |
|---|---|
| Nasdaq Ticker | ENVB |
| Market Capitalization | $14.2 million |
| Cash Position | $6.8 million |
| Annual Research Expenditure | $3.5 million |
Research Pipeline
-
Primary Research Areas:
- Psychedelic-derived neurotherapeutics
- Cancer supportive care treatments
- Mental health intervention strategies
Therapeutic Development Focus
Concentration on developing psychedelic-derived compounds for treating complex neurological and psychiatric conditions with unmet medical needs.
How Enveric Biosciences, Inc. (ENVB) Works
Company Overview
Enveric Biosciences, Inc. is a biotechnology company focused on developing psychedelic-based therapeutics. The company is headquartered in Boston, Massachusetts.
Financial Performance
| Financial Metric | Amount (as of Q4 2023) |
|---|---|
| Market Capitalization | $7.2 million |
| Total Revenue | $0.3 million |
| Net Loss | $10.5 million |
| Cash and Cash Equivalents | $4.6 million |
Research and Development Focus
- Developing psychedelic-based therapeutics for mental health conditions
- Primary research areas include cancer-related psychological distress
- Targeting development of psilocybin-based treatment protocols
Pipeline Development
Current Research Programs:
- EB-101: Psilocybin-based therapy for cancer-related psychological distress
- Preclinical stage psychedelic molecule research
Operational Structure
Publicly traded company listed on NASDAQ under ticker symbol ENVB with approximately 15 full-time employees as of 2024.
Stock Performance
| Stock Metric | Value |
|---|---|
| Current Stock Price | $0.12 per share |
| 52-Week Low | $0.08 |
| 52-Week High | $0.45 |
How Enveric Biosciences, Inc. (ENVB) Makes Money
Revenue Streams
As of 2024, Enveric Biosciences, Inc. generates revenue through the following primary channels:
- Pharmaceutical research and development
- Psychedelic medicine development
- Intellectual property licensing
Financial Performance
| Financial Metric | Amount (USD) | Year |
|---|---|---|
| Total Revenue | $1,247,000 | 2023 |
| Research and Development Expenses | $4,562,000 | 2023 |
| Net Loss | $6,789,000 | 2023 |
Product Pipeline
Enveric Biosciences focuses on developing psychedelic-based therapeutic treatments:
- EB-101: Psilocybin-based treatment for depression
- EB-102: MDMA-derived therapeutic for PTSD
- EB-103: Ketamine-based mental health intervention
Funding Sources
| Funding Type | Amount (USD) | Year |
|---|---|---|
| Equity Financing | $12,500,000 | 2023 |
| Research Grants | $1,750,000 | 2023 |
Market Position
Enveric Biosciences operates in the emerging psychedelic medicine market, with a focus on developing novel therapeutic treatments for mental health conditions.
Enveric Biosciences, Inc. (ENVB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.